vTv Therapeutics Completes Enrollment in Phase 3 Type 1 Diabetes Trial
vTv Therapeutics has finished enrolling patients in its CATT1 Phase 3 study of cadisegliatin, with topline results expected by mid-2027.
vTv Therapeutics has completed enrollment in its Phase 3 CATT1 clinical trial evaluating cadisegliatin as a treatment for Type 1 diabetes, the company announced, marking a significant milestone in the drug's development timeline.
The completion of enrollment moves the trial into its next phase, with the company targeting topline results sometime in mid-2027. Reaching full enrollment in a Phase 3 study is a critical procedural threshold, as it allows researchers to begin accumulating the outcome data necessary for a regulatory submission.
Read more FTC Settles With Martial Arts Franchisor for $1.85M Over Deceptive Claims →
Cadisegliatin is the investigational compound at the center of vTv's Type 1 diabetes program. Phase 3 trials represent the final and largest stage of human clinical testing before a drug can seek approval from the U.S. Food and Drug Administration, typically requiring hundreds to thousands of participants and designed to confirm efficacy and monitor adverse reactions at scale.
Type 1 diabetes affects millions of Americans and is characterized by the immune system's destruction of insulin-producing cells in the pancreas, leaving patients dependent on external insulin therapy. New treatment approaches that could complement or reduce that dependence remain an active area of pharmaceutical research and investment.
The CATT1 enrollment completion positions vTv on a roughly two-year glide path toward its data readout, a timeline that investors and analysts in the biotech sector will watch closely. Continue reading at GlobeNewswire - Industry News on Financial Services.
